We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesInternational Stem Cell Corp

International Stem Cell Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.16 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
24996
Market Cap
0.82M
P/E
5.10

Momentum Score

…

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.14
Low
0.16
High
52 Week Price Range
0.06
Low
0.26
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

International Stem Cell Corporation develops stem cell therapies and cell-derived products using parthenogenetic technology for regenerative medicine and cosmetic applications. Long-term growth drivers may include progress in R&D and regulatory milestones, commercialization or licensing of product lines, and broader adoption of regenerative treatments. Investors may find the company attractive for its differentiated platform and exposure to therapeutic and consumer markets, although outcomes depend on execution.
Material risks include early-stage execution and regulatory uncertainty, limited operating history and OTC liquidity, potential need for additional financing and competition from larger biotech firms.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.16
Dividend Yield
1.41%
Revenue TTM
8.33M
Revenue Per Share
1.04
Gross Profit TTM
4.24M
Debt / Equity
-
ROE
78.65%
Net Debt
2.58M
ROCE
-36.60%
Diluted EPS TTM
0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -0.33M -0.90M -2.72M -4.26M -2.13M
Net income -0.33M -0.90M -2.72M -4.26M -2.13M
Selling general administrative 4.60M 5.47M 6.18M 9.88M 8.10M
Gross profit 4.91M 4.24M 4.35M 5.54M 7.02M
Reconciled depreciation 0.22M 0.26M 0.25M 0.28M 0.31M
Ebit - -1.67M -2.61M -4.19M -2.87M
Ebitda 0.02M -0.51M -2.36M -3.90M -1.77M
Non operating income net other - - 0.21M 1.54M -
Operating income -0.18M -1.92M -2.82M -5.73M -3.47M
Interest expense 0.14M 0.13M 0.11M 0.08M 0.05M
Tax provision - - - - 0.00M
Net interest income -0.14M -0.13M -0.11M -0.08M -0.05M
Total revenue 8.18M 7.18M 7.13M 9.47M 11.09M
Total operating expenses 8.36M 9.10M 7.17M 15.20M 14.56M
Cost of revenue 3.27M 2.94M 2.78M 3.93M 4.07M
Total other income expense net -0.01M 1.15M 0.21M 1.54M 1.39M
Net income from continuing ops -0.33M -0.90M -2.72M -4.26M -2.13M
Net income applicable to common shares - -0.90M -2.72M -4.26M -2.13M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 5.13M 4.95M 5.29M 6.62M 7.80M
Intangible assets 0.88M 0.95M 1.26M 1.33M 2.67M
Other current assets 0.09M 0.14M 0.17M 0.21M -
Total liab 9.65M 9.53M 5.32M 9.51M 5.26M
Total stockholder equity -4.52M -4.59M -4.33M -2.89M 2.54M
Other current liab 0.25M 0.25M 0.74M 0.25M 2.00M
Common stock - 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -110.34M -110.01M -109.11M -106.39M -106.66M
Other liab - - - 0.21M 0.18M
Other assets - 0.41M 0.43M 0.45M 0.88M
Cash 0.74M 0.17M 0.69M 0.48M 1.07M
Total current liabilities 4.63M 4.28M 1.48M 1.91M 5.08M
Net debt 2.58M 2.77M 2.44M 1.89M 0.97M
Short long term debt 3.33M 2.94M 0.14M - 2.04M
Property plant equipment - 1.25M 0.53M 1.39M 0.47M
Total current assets 2.96M 2.33M 2.18M 3.45M 3.77M
Net tangible assets - -5.54M -1.30M -4.23M -0.14M
Net receivables 0.75M 0.84M 0.40M 1.51M 0.65M
Long term debt - - 2.99M 2.37M -
Inventory 1.38M 1.18M 0.92M 1.25M 1.50M
Accounts payable 0.32M 0.51M 0.75M 0.65M 0.46M
Common stock total equity - - 0.01M 0.01M -
Preferred stock total equity - - 0.01M 0.01M -
Retained earnings total equity - - -109.11M -106.39M -
Non currrent assets other 0.29M 0.37M 0.94M 0.36M 0.81M
Non current assets total 2.17M 2.61M 2.73M 3.17M 4.03M
Capital lease obligations 0.95M 1.13M 1.19M 1.08M -
Long term debt total - - - 0.21M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01M -0.04M -0.11M -0.49M -0.66M
Change to liabilities - 0.15M -0.55M 0.27M -0.09M
Total cashflows from investing activities - -0.04M -0.11M -0.49M -0.66M
Net borrowings - 0.82M 0.65M 1.30M 2.00M
Total cash from financing activities 0.25M 0.82M 0.65M 1.30M 2.51M
Change to operating activities - -0.26M -0.51M 0.38M 0.35M
Net income -0.33M -0.90M -2.72M -4.26M -2.13M
Change in cash 0.57M -0.52M 0.20M -0.59M 0.77M
Begin period cash flow 0.17M 0.69M 0.48M 1.07M 0.30M
End period cash flow 0.74M 0.17M 0.69M 0.48M 1.07M
Total cash from operating activities 0.33M -1.30M -0.34M -1.40M -1.08M
Issuance of capital stock - - - 0.00M 0.50M
Depreciation 0.22M 0.26M 0.25M 0.28M 0.31M
Other cashflows from investing activities - - -0.08M -0.33M -0.48M
Change to inventory -0.11M -0.27M 0.32M 0.12M -0.29M
Change to account receivables 0.10M -0.44M 1.11M -0.86M -0.19M
Sale purchase of stock - - - - 0.66M
Other cashflows from financing activities - - - - 1.85M
Change to netincome - 0.16M 1.14M 2.09M 0.96M
Capital expenditures 0.01M 0.02M 0.03M 0.16M 0.18M
Change receivables - - 1.11M -0.86M -0.19M
Cash flows other operating - - 0.12M 0.96M 0.35M
Cash and cash equivalents changes - - 0.20M -0.59M 0.77M
Change in working capital -0.23M -0.82M 0.62M -0.16M -0.21M
Stock based compensation 0.40M 0.64M 1.28M 2.09M -
Other non cash items 0.27M 0.41M 0.37M 0.08M 0.03M
Free cash flow 0.32M -1.34M -0.45M -1.89M -1.74M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ISCO
International Stem Cell Corp		 -
-%		 0.16 5.10 - 0.10 - 0.43 5.24
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

International Stem Cell Corp

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

9745 Businesspark Avenue, San Diego, CA, United States, 92131

760 940 6383

https://www.internationalstemcell.com

29

Name Title Year Born
Dr. Andrey Semechkin Ph.D. Co-Chairman & CEO 1960
Dr. Russell Kern Ph.D. Exec. VP, Chief Scientific Officer, Principal Financial Officer & Director 1986
Ms. Rebecca McGee M.B.A. Pres of Lifeline Cell Technology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…